Terms: = Prostate cancer AND STAT5B, STAT5, 6777, ENSG00000173757, P51692 AND Prognosis
5 results:
1. PRL-mediated stat5b/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling.
Yang T; Chi Y; Wang X; Xu C; Chen X; Liu Y; Huang S; Zhu X; Zhang H; Zhuo H; Wu D
Cell Death Dis; 2024 Feb; 15(2):128. PubMed ID: 38341429
[TBL] [Abstract] [Full Text] [Related]
2. Targeting the cellular schizophrenia. Likely employment of the antipsychotic agent pimozide in treatment of refractory cancers and glioblastoma.
Elmaci I; Altinoz MA
Crit Rev Oncol Hematol; 2018 Aug; 128():96-109. PubMed ID: 29958636
[TBL] [Abstract] [Full Text] [Related]
3. Growth hormone enhances LNCaP prostate cancer cell motility.
Nakonechnaya AO; Shewchuk BM
Endocr Res; 2015; 40(2):97-105. PubMed ID: 25330355
[TBL] [Abstract] [Full Text] [Related]
4. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways.
Colombatti M; Grasso S; Porzia A; Fracasso G; Scupoli MT; Cingarlini S; Poffe O; Naim HY; Heine M; Tridente G; Mainiero F; Ramarli D
PLoS One; 2009; 4(2):e4608. PubMed ID: 19242540
[TBL] [Abstract] [Full Text] [Related]
5. Anemia, tumor hypoxemia, and the cancer patient.
Varlotto J; Stevenson MA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):25-36. PubMed ID: 16111569
[TBL] [Abstract] [Full Text] [Related]
